Cabaletta Bio reported a second quarter 2026 net loss of $51.0 million, or $0.34 per share, as it continues to advance its late-stage clinical pipeline. The company is maintaining its timeline for its lead cell therapy candidate, rese-cel, with primary registrational milestones focused on 2027.
Key Highlights
- Clinical data from the registrational RESET-Myositis cohort is on track for reporting in mid-2027 to support a BLA submission in the second half of 2027.
- Cash, cash equivalents, and short-term investments totaled $225.1 million as of June 30, 2026, which is projected to fund operations into mid-2027.
- A new registrational study for approximately 25 patients with systemic sclerosis-associated interstitial lung disease is expected to initiate in the fourth quarter of 2026.